Drugs / PF-04531083
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01127906 | Jun → Sep 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01103739 | Mar → May 2010 | chronic pain syndrome | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01012310 | Nov 2009 → Feb 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01512160 | Oct 2011 → Mar 2012 | — | Pfizer | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01119235 Comparator | May → Jul 2010 | chronic pain syndrome | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-04531083 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01103739 ↗ |
| Known as | PF-4531083 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3589904 ↗ |
| Action | Inhibit | “Sodium channel protein type X alpha subunit blocker” CHEMBL3589904 ↗ |
| Modality | Small molecule | — CHEMBL3589904 ↗ |
| Route | Oral | “multiple oral doses” NCT01012310 ↗ |
| Target | SCN10A | “Sodium channel protein type X alpha subunit blocker” CHEMBL3589904 ↗ |